Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Immunocore Holdings (IMCR) Change in Account Payables (2023 - 2025)

Immunocore Holdings (IMCR) has disclosed Change in Account Payables for 3 consecutive years, with $1.4 million as the latest value for Q4 2025.

  • Quarterly Change in Account Payables fell 75.9% to $1.4 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$2.5 million through Dec 2025, down 133.77% year-over-year, with the annual reading at -$2.5 million for FY2025, 133.77% down from the prior year.
  • Change in Account Payables hit $1.4 million in Q4 2025 for Immunocore Holdings, up from -$287000.0 in the prior quarter.
  • In the past five years, Change in Account Payables ranged from a high of $6.0 million in Q2 2023 to a low of -$6.9 million in Q2 2025.
  • Historically, Change in Account Payables has averaged $620083.3 across 3 years, with a median of $565500.0 in 2025.
  • Biggest YoY gain for Change in Account Payables was 244.05% in 2025; the steepest drop was 254.53% in 2025.
  • Year by year, Change in Account Payables stood at $3.8 million in 2023, then surged by 56.7% to $5.9 million in 2024, then crashed by 75.9% to $1.4 million in 2025.
  • Business Quant data shows Change in Account Payables for IMCR at $1.4 million in Q4 2025, -$287000.0 in Q3 2025, and -$6.9 million in Q2 2025.